Age, life expectancy influence termination of PSA screening

Age, life expectancy influence termination of PSA screening

(HealthDay) -- Most primary care providers consider both a man's age and life expectancy in deciding whether to discontinue prostate-specific antigen (PSA) screenings, but multiple factors are involved in this decision, according to a study published online April 19 in Cancer.

Craig E. Pollack, M.D., M.H.S., from the Johns Hopkins School of Medicine in Baltimore, and colleagues surveyed 125 primary providers from a large, university-affiliated primary care practice regarding their current , factors that influence their decision to discontinue screening, and barriers to discontinuing screening.

The researchers found that 59.3 percent of the primary care providers took both age and into account in their decisions to discontinue PSA screening, compared with 12.2 percent who did not consider either. Provider characteristics or practice styles were not associated with taking patient age and life expectancy into account. The majority (66.4 percent) of providers reported difficulty in assessing life expectancy and they differed in the age at which they typically stopped screening patients. Patient expectation and were the most frequently cited barriers to discontinuing PSA screening, cited 74.4 and 66.4 percent of the time, respectively.

"Although age and life expectancy often figured prominently in decisions to use screening, providers faced multiple barriers to discontinuing routine ," the authors write.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Baseline PSA predicts risk of death from prostate cancer

Jul 08, 2010

Men who have a baseline PSA value of 10 or higher the first time they are tested are up to 11 times more likely to die from prostate cancer than are men with lower initial values, according to Duke University Medical Center ...

Mass prostate cancer screening doesn't reduce deaths: study

Jan 06, 2012

There's new evidence that annual prostate cancer screening does not reduce deaths from the disease, even among men in their 50s and 60s and those with underlying health conditions, according to new research led by Washington ...

Recommended for you

XenOPAT, mouse models for personalized cancer treatment

14 hours ago

On September 8th, the company XenOPAT SL, a spin-off of the Institute of Biomedical Research (IDIBELL) and the Catalan Institute of Oncology (ICO) was established with the aim of bringing the company the latest scientific ...

User comments